

Removal of temporary benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Thiamine HCl 100 mg/ml Injection (DIN 02243525), manufactured by Cytex Pharmaceuticals Inc., and Thiamiject 100 mg/ml Injection (DIN 02193221), manufactured by Omega Laboratories Limited, Vitamin B1 100 mg/ml Injection USP (DIN 00816078), manufactured by Sandoz Canada Inc., was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)* as of May 23, 2012.

Cytex Pharmaceuticals Inc. has advised Alberta Blue Cross that the shortage of Thiamine HCl 100 mg/ml Injection (DIN 02243525) has been resolved.

As a result, Vitamin B1 100 mg/ml Injection USP (DIN 00816078) will no longer be considered a temporary benefit for the *ADBL* after October 8, 2014.

Due to the shortage of Acetylcysteine 20% Inhalation Solution (DIN 02243098), manufactured by Sandoz Canada Inc., Acetylcysteine 20% Inhalation Solution (DIN 02300435), manufactured by Alveda Pharmaceuticals Inc., was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)* as of August 20, 2013.

Sandoz Canada Inc. has advised Alberta Blue Cross that the shortage of Acetylcysteine 20% Inhalation Solution (DIN 02243098) has been resolved.

As a result, Acetylcysteine 20% Inhalation Solution (DIN 02300435) will no longer be considered a temporary benefit for the *ADBL* after October 8, 2014.

Due to the shortage of Sandostatin 200 mcg/ml Injection (DIN 02049392), manufactured by Novartis Pharmaceuticals Canada Inc., Octreotide Acetate Omega 200 mcg/ml Injection (DIN 02248642), manufactured by Omega Laboratories Limited, was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)* as of September 5, 2013.

Novartis Pharmaceuticals Canada Inc. has advised Alberta Blue Cross that the shortage of Sandostatin 200 mcg/ml Injection (DIN 02049392) has been resolved.

As a result, Octreotide Acetate Omega 200 mcg/ml Injection (DIN 02248642) will no longer be considered a temporary benefit for the *ADBL* after October 8, 2014.

Due to the shortage of Apo-Folic Acid 5 mg Tablet (DIN 00426849), manufactured by Apotex Inc., Jamp-Folic Acid 5 mg Tablet (DIN 02366061), manufactured by Jamp Pharma Corporation, was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)* as of December 16, 2013.

Apotex Inc. has advised Alberta Blue Cross that the shortage of Apo-Folic Acid 5 mg Tablet (DIN 00426849) has been resolved.

As a result, Jamp-Folic Acid 5 mg Tablet (DIN 02366061) will no longer be considered a temporary benefit for the *ADBL* after October 8, 2014.

... continued from previous page

Due to the shortage of Apo-Furosemide 20 mg Tablet (DIN 00396788), manufactured by Apotex Inc., Novo-Semide 20 mg Tablet (DIN 00337730), manufactured by Teva Canada Limited, and Furosemide 20 mg Tablet (DIN 02351420), manufactured by Sanis Health Inc., pms-Furosemide 20 mg Tablet (DIN 02247493), manufactured by Pharmascience Inc., was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)* as of March 13, 2014.

Apotex Inc., Teva Canada Limited and Sanis Health Inc. have advised Alberta Blue Cross that the shortages of Apo-Furosemide 20 mg Tablet (DIN 00396788), Novo-Semide 20 mg Tablet (DIN 00337730), and Furosemide 20 mg Tablet (DIN 02351420) have been resolved.

As a result, pms-Furosemide 20 mg Tablet (DIN 02247493) will no longer be considered a temporary benefit for the *ADBL* after October 8, 2014.

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage of Acetylcysteine 20% Inhalation Solution (DIN 02243098) has been resolved. Due to the long-term nature of this shortage, a 1-month transition period has been applied and as a result, the LCA price policy will be reapplied to the following grouping effective **October 8, 2014**.

ACETYLCYSTEINE

20 % INHALATION SOLUTION

00002243098	ACETYLCYSTEINE	SDZ	\$ 0.7000
00002091526	MUCOMYST	WSP	\$ 0.7200

Alberta Blue Cross has been advised by Cytex Pharmaceuticals Inc. that the shortage of Thiamine HCl 100 mg/ml Injection (DIN 02243525) has been resolved. Due to the long-term nature of this shortage, a 1-month transition period has been applied and as a result, the LCA price policy will be reapplied to the following grouping effective **October 8, 2014**.

THIAMINE HCL

100 MG / ML INJECTION

00002193221	THIAMIJECT	OMG	\$ 1.1880
00002243525	THIAMINE HCL	CYT	\$ 1.1880

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations call centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)



*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ABC 82320.478 2014/09